One could argue that CMS is restricting coverage of a particular instance of an accelerated approval and a set of potential approvals for a narrowly defined sub-class of beta amyloid-directed monoclonal antibodies. And this particular decision has no universal implications outside of this sub-class.
CMS’s Decision To Restrict Coverage Of Aduhelm Very Unlikely To Impact Other Accelerated Approvals In Other Classes
